As evidenced by recent legislative battles with it at the focus, the health care industest is often resistant to modify for a variety of reasons. The high stress of many industest occupations, as well as the strict regulations over care, can sometimes lead to stasis for innovation.
However, TechCrunch reported that Doctolib, a Paris-based startup and the leading platform for booking doctor appointments in France, announced Tuesday (Oct. 13) that it had secured $20 million in Series B funding to take its brand of medicinal revolution all across Europe. CEO Stanislas Niox-Chateau explained why he considers both patients and medical professionals alike will flock to Doctolib.
“Our goal is to consolidate our leading position in France and expand to other European countries,” Niox-Chateau declared. “We started 18 months ago, and we now have 5,000 doctors applying our platform every day in order to manage their bookings. We have around a hundred clinics, and we obtain 2 million monthly unique visitors. When it comes to traction, we are adding 600 doctors per month, and we plan to double this number in the coming weeks.”
The company claims that Doctolib’s appointment management system can support doctors reduce patient no-reveal rates from 10 percent to about 2.5 percent. And with a consumer base seeing to create more bookings than the restaurant industest, Niox-Chateau explained, the potential for convenience and profit is just waiting to be snatched up.
Doctolib will have to work rapid to corner the European market on doctor appointments, though. VentureBeat explained how ZocDoc, a similar New York-based service, and Lybrate, an India-based management system, have both garnered millions and, in ZocDoc’s case, billions of dollars in valuation.
Beating its competitors would be tough enough, but testing to revolutionize an entire industest of medical professionals is the fight Doctolib has chosen. With a fresh round of funding, though, things might not see so daunting.
To check out what else is HOT in the world of payments, click here.
Leave a Reply